The CANTOS trial, which demonstrated that canakinumab (an IL-1β inhibitor) significantly reduced recurrent cardiovascular events in patients with a history of myocardial infarction, highlights the potential benefits of such therapeutic approaches. This evidence concerns the gene IL1B and myocardial infarction.